pHOXBIO Announces Breakthrough Clinical Trial Results Concluding Prophylactic Nasal Spray Prevents Infection from SARS-CoV-2
– pHOXWELL significantly reduced SARS-CoV-2 infection by 63% with tolerability comparable to placebo in high-risk population of healthcare workers – Novel self-administered nasal spray designed to augment existing preventive measures for SARS-CoV-2, including PPE and vaccines – Regulatory filing initiated in India for SARS-CoV-2 prevention claim – Company exploring strategic alternatives to make product accessible in…
